PepGen Inc. 8K

PepGen Inc. announced second quarter 2026 financial results and a positive DSMB recommendation to escalate dosing and advance its PGN-EDODM1 FREEDOM2-DM1 clinical program, while confirming cash runway into Q4 2027.

On August 6, 2026, PepGen Inc. reported its financial results for the quarter ended June 30, 2026 and provided corporate and clinical program updates, highlighting that an independent Data and Safety Monitoring Board recommended advancing its PGN-EDODM1 FREEDOM2-DM1 Phase 2 trial to the highest 12.5 mg/kg dose cohort and allowing dose escalation in the open-label extension, that the 10 mg/kg cohort is fully enrolled with data expected in November 2026 and 12.5 mg/kg cohort data expected in the first half of 2027, and that the company had $117.2 million in cash, cash equivalents and marketable securities as of June 30, 2026, which it believes will fund operations into the fourth quarter of 2027, alongside reporting reduced R&D expenses, slightly higher G&A expenses, and a narrower net loss compared to the prior-year quarter.

Filing Facts

CIK

1835597

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-336767

Alert Tier

6